menu

Medical Program: How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC

close
How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Immune checkpoint inhibitors are now the standard of care for almost all of our patients with non-small cell lung cancer. And here to give us a look into how that’s impacted our patients and practices is Dr. Stephen Liu, Associate Professor of Medicine at the Lombardi Comprehensive Cancer Center of Georgetown University.

Presenters

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Immune checkpoint inhibitors are now the standard of care for almost all of our patients with non-small cell lung cancer. And here to give us a look into how that’s impacted our patients and practices is Dr. Stephen Liu, Associate Professor of Medicine at the Lombardi Comprehensive Cancer Center of Georgetown University.

Presenters

Facebook Comments

Programs 4/20/21